Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Lummy licenses cancer immunotherapy rights from Argos

Executive Summary

Argos Therapeutics Inc. granted Chongqing Lummy Pharmaceutical Co. Ltd. and its Lummy (Hong Kong) Co. Ltd. subsidiary exclusive rights to develop, manufacture, and sell its Phase III renal cell carcinoma candidate AGS003 in China, Hong Kong, Taiwan, and Macau.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Contract
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register